Mercola.com interview transcript in which Gonzalez-Lima argues the FDA serotonin warning came from a handful of anaesthetised parathyroid-surgery cases with repeated open-neck flushing at high doses, that the Mayo Clinic published a rebuttal, and that Canada limits its warning to that application while the FDA did not.
To my knowledge, there’s never been more than five cases, where the patients were anesthetized, and they still had SSRIs [in their system], and they did repeated flushing in the open neck with methylene blue, which exceeded these doses that we have been talking about.
Mercola.com interview transcript in which Gonzalez-Lima argues the FDA serotonin warning came from a handful of anaesthetised parathyroid-surgery cases with repeated open-neck flushing at high doses, that the Mayo Clinic published a rebuttal, and that Canada limits its warning to that application while the FDA did not. C2 primary source for the Gonzalez-Lima argument: published 2022-05-01 ("Analysis by Dr. Joseph Mercola … May 01, 2022"). Recorded as Mercola.com and Dr. Gonzalez-Lima say it, attributed. Two further statements from the same page, quoted in the adjacent C2 row: "Canada limits the warning to that particular application, but our FDA went beyond that to any kind of serotonergic drug." and "I think there is absolutely no evidence for oral methylene blue having interactions in this low-dose range with any SSRIs." A PDF transcript of the interview (Mercola ImageServer, 2022/May) also exists. No Internet Archive capture of this URL was found (available API returned no snapshot). Page carries Mercola's own banner "This is an older article that may not reflect Dr. Mercola's current view on this topic". Also filed as MTO-62 (claims C10, C2). Study type: other.
